Please assess the completion status of the following clinical trial:

Trial Title: Efficacy and Safety of aerosolizedDornase Alfa Administration in Patients With COVID19 Induced ARDS (COVIDORNASE)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
inclusion criteria~* Adult patient (age ≥ 18 years old);~* Hospitalized in intensive care ;~* Severe COVID-19 pneumonia (positive diagnosis by RT-PCR or SARS-CoV-2 antigen test on nasopharyngeal or deep respiratory specimen and/or evocative thoracic scan: frosted glass opacities, consolidation, cross-linking, thickening of interlobular septa, peripheral nodules) with ARDS criteria according to Berlin criteria (PaO2/FiO2 ≤ 300 and PEP ≥ 5).~* With respiratory assistance (intubated or NIV or ONHD) for less than 8 days;~* With an expected duration of respiratory assistance \> 48 hours;~* Carrier of an arterial catheter ;~* For which 4 PaO2/FiO2 values on arterial blood over the last 24 hours are available;~Exclusion Criteria:~* Known hypersensitivity to Dornase alfa or any of the excipients;~* Pregnant or breastfeeding status;~* Patient with legal protection.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Experimental group (Type: EXPERIMENTAL): Dornase alfa will be administered by nebulization, at a dose of 2500 IU twice daily, 12 hours apart, for 7 consecutive days, using a vibrating mesh nebulizer. The remainder of the management will be performed in accordance with good practice, including mechanical ventilation (protective ventilation, PEEP \> 5 cmH2O, tracheal balloon pressure checking every 4 hours or automatic device, 30° head of the bed elevation, tidal volume 6-8mL/kg, plateau pressure \< 30cmH2O), neuromuscular blockers if necessary, prone position if PaO2/FiO2\<150, early enteral nutrition, glycemic control, a sedation protocol based on the RASS score.
- Control group (Type: ACTIVE_COMPARATOR): Patients will receive the usual care in accordance with good practice.

Based on this trial design, predict the completion outcome and termination type (if applicable).